Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) – CareAdvantage. This is a data-driven, holistic approach in which JJMD partners with hospitals and other healthcare providers to provide a range of benefits, tailored to the customer’s specific needs and priorities.
The healthcare marketplace is changing, with intensifying pressure to meet the ‘triple aim’ of improving outcomes, increasing patient satisfaction and reducing costs. As the focus shifts from volume to value, there is a growing need for new delivery models, resulting in rapid transformation for hospital systems, clinicians and their patients.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8119051-johnson-medical-devices-careadvantage/
Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.
“The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
The millions of women who experience bladder leakage now have a new option to strengthen and tone away their problem instead of covering it up with pads.
The PeriCoach System is a discreet device and smartphone app that helps women perform at-home pelvic floor muscle training, exercises recommended by the American College of Physicians as first-line treatment for urinary incontinence. PeriCoach is the only system that includes a web portal allowing clinicians to remotely monitor their patients’ progress.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7543451-pericoach-fda-approval/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
The MedTech Industry’s Premier Design Competition is now accepting entries. Proudly presented by UBM Canon and MD+DI, the Medical Design Excellence Awards program has provided market visibility to over 500 innovative MedTech products that are changing the face of healthcare today. The MDEA also celebrates the achievements of medical product manufacturers, their suppliers, and the many people behind the scenes—engineers, scientists, designers, and clinicians—who are responsible for these groundbreaking innovations.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58607-2013-medical-design-excellence-awards-call-for-entries-medtech-mdea13
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced plans to launch its new epilepsy-focused educational website, www.Epilog.us, at the American Epilepsy Society (AES) annual meeting, December 3-5, 2011. The new website will be featured at the Upsher-Smith booth (# 102) and marks an important landmark in the Company’s commitment to the epilepsy community.
To view Multimedia News Release go to http://www.multivu.com/mnr/53440-upsher-smith-launches-new-epilepsy-focused-website
Current drug shortages in the U.S., while disruptive and of increasing concern to patients, clinicians and policymakers, are limited primarily to generic injectables and a few key disease areas, according to an IMS Institute for Healthcare Informatics study released today. The new study, Drug Shortages: A Closer Look at Products, Suppliers and Volume Volatility, offers a comprehensive examination of drug shortages and recommends that healthcare stakeholders work toward the creation of an early warning system to minimize future patient care disruptions.
To multimedia News Release, go to http://www.multivu.com/mnr/53215-ims-institute-for-healthcare-informatics-drug-shortage-study
BD AutoShield™ Duo is a next generation, 5mm safety-engineered pen needle designed to protect healthcare workers from needlestick injuries and blood exposure. It is now available in the US from BD Medical, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company.
Protection After Use: The BD AutoShield™ Duo is the only pen needle with front and back-end needle protection. The safety mechanisms activate automatically after use, virtually eliminating the risk of exposure to contaminated needles for clinicians and others.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52948-bd-autoshield-introduces-worlds-first-safety-engineered-pen-needle
Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, has announced the first nine U.S. cities for a series of evening events to introduce clinicians to the Selenia Dimensions 2D/3D breast tomosynthesis system and gain hands-on experience with this new technology.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/hologic/50094/
After a successful pilot program in October 2009, Cancer Treatment Centers of America (CTCA) is introducing an innovative approach to cancer treatment this July at each of its four hospitals in suburban Chicago, Philadelphia, Tulsa and suburban Phoenix. Called “Patient Empowered CareSM,” this advancement in the patient treatment delivery process offers patients an average of between two and three hours with a dedicated team of specialized oncology physicians and clinicians.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cancercenter/44523/
